- Home
- RLYB
RLYB
Rallybio Corporation
as 10-24-2025 3:56pm EST
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 24.1M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 290.8K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.22 - $1.24 | Next Earning Date: | 11-07-2025 |
| Revenue: | $761,000 | Revenue Growth: | 154.51% |
| Revenue Growth (this year): | -14.47% | Revenue Growth (next year): | N/A |
Latest Rallybio Corporation News
RLYB Breaking Stock News: Dive into RLYB Ticker-Specific Updates for Smart Investing
Business Wire
4 months ago
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
Business Wire
6 months ago
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
Business Wire
6 months ago
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
MT Newswires
6 months ago
Evercore ISI Downgrades Rallybio to In Line From Outperform
Zacks
7 months ago
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
MT Newswires
7 months ago
HC Wainwright Downgrades Rallybio to Neutral From Buy
Clinical Trials Arena
7 months ago
Rallybio drops drug for rare maternal disorder following Phase II fail
MT Newswires
7 months ago
Rallybio Terminates RLYB212 Development for Rare Immune Disorder; Shares Fall
Compare RLYB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLYB Rallybio Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.